Cancer is undoubtedly a disease of ageing. Therefore, it is not that surprising that a recent study published in the Journal of Clinical Oncology found that cancer diagnoses in the United States are likely to increase by 45% by the year 2030, partly as a result of the ageing of the US population. Although this is not entirely unexpected, it emphasizes the need for specific research geared towards developing efficacious and cost-effective therapies for this population.
This study also found that cancer incidence in ethnic minorities in the United States is likely to double by 2030. Indeed, as immigration increases globally, countries besides the United States are also likely to face the oncological challenges and questions that come with having a more ethnically diverse population than that of a century ago. For example, some cancers that are particularly difficult to treat, such as those of the liver, are more prevalent in some non-white populations. In addition, there is a need to understand more about racial differences in cancer biology.
This is a preview of subscription content, access via your institution
